BNP PARIBAS ASSET MANAGEMENT Holding S.A. Reduces Position in Repligen Co. (NASDAQ:RGEN)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 12.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 257,501 shares of the biotechnology company's stock after selling 35,239 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.46% of Repligen worth $32,461,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in RGEN. YHB Investment Advisors Inc. purchased a new stake in Repligen in the 1st quarter worth $26,000. Lazard Asset Management LLC grew its position in shares of Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after buying an additional 136 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company's stock worth $43,000 after purchasing an additional 146 shares during the last quarter. Principal Securities Inc. purchased a new position in Repligen during the 4th quarter worth approximately $48,000. Finally, CWM LLC raised its stake in Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 60 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on RGEN shares. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Wednesday, July 31st. Stephens reissued an "overweight" rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday. They issued an "overweight" rating and a $180.00 price target for the company. Guggenheim began coverage on Repligen in a report on Tuesday, June 18th. They set a "neutral" rating for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a "hold" rating to a "buy" rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $188.38.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 4,465 shares of the firm's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Anthony Hunt acquired 2,000 shares of Repligen stock in a transaction on Friday, June 14th. The shares were purchased at an average cost of $124.08 per share, for a total transaction of $248,160.00. Following the purchase, the chief executive officer now directly owns 165,177 shares of the company's stock, valued at approximately $20,495,162.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the firm's stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Price Performance

Repligen stock traded up $0.18 during midday trading on Friday, reaching $150.93. 3,728,546 shares of the stock traded hands, compared to its average volume of 667,960. The stock's fifty day moving average is $141.15 and its 200-day moving average is $161.23. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.43 billion, a P/E ratio of 603.72, a PEG ratio of 5.27 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $154.07 million for the quarter, compared to analysts' expectations of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm's quarterly revenue was down 3.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.53 EPS. As a group, equities research analysts anticipate that Repligen Co. will post 1.45 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.